N. Brock

发表

Comparative pharmacologic study in vitro and in vivo with cyclophosphamide (NSC-26271), cyclophosphamide metabolites, and plain nitrogen mustard compounds.

N. Brock, 1976, Cancer treatment reports.

Chemotherapeutic Action of a Cyclic Nitrogen Mustard Phosphamide Ester (B 518-ASTA) in Experimental Tumours of the Rat

N. Brock, H. Arnold, F. Bourseaux, 1958, Nature.

Special contributed article. Models in cytostatic chemotherapy

N. Brock, B. Schneider, 1984 .

Methodological problems in the quantitative assessment of carcinogenesis in long-term studies.

N. Brock, B. Schneider, 1975, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

A Screening System for Anti-Cancer Agents Based on the Therapeutic Index

N. Brock, B. Schneider, 1965 .

Basic principles in preclinical cancer chemotherapy

N. Brock, J. Pohl, B. Schneider, 2005, Journal of Cancer Research and Clinical Oncology.

Ideas and reality in the development of cancer chemotherapeutic agents, with particular reference to oxazaphosphorine cytostatics

N. Brock, 2004, Journal of Cancer Research and Clinical Oncology.

The history of the oxazaphosphorine cytostatics

N. Brock, 1996, Cancer.

Basis and new developments in the field of oxazaphosphorines.

H. Sindermann, N. Brock, P. Hilgard, 1988, Cancer investigation.

Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.

R. Voigtmann, N. Brock, J. Schnitker, 1979, Cancer treatment reports.

[Toxicology of dilazep, a new coronary active agent].

H. Abel, N. Brock, D. Lenke, 1972, Arzneimittel-Forschung.

Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.

N. Brock, J. Pohl, U. Niemeyer, 1979, Arzneimittel-Forschung.

Pharmacological Aspects on the Treatment of Prostatic Carcinoma with Stilbestrol Diphosphate

N. Brock, 1971 .

Pharmacological and toxicological properties of azelastine, a novel antiallergic agent.

N. Brock, H. Zechel, U. Achterrath-Tuckermann, 1981, Arzneimittel-Forschung.

Oxazaphosphorine cytostatics: past-present-future. Seventh Cain Memorial Award lecture.

N. Brock, 1989, Cancer research.

[Experiences with N-Lost phosphamide esters].

K. Mainzer, N. Brock, H. Gerhartz, 1970, Deutsche medizinische Wochenschrift.

Pharmacokinetics and mechanism of action of detoxifying low-molecular-weight thiols

S. Orrenius, N. Brock, J. Pohl, 2004, Journal of Cancer Research and Clinical Oncology.

Metabolism of cyclophosphamide

N. Brock, H. Hohorst, Prof. Dr. med. Norbert Brock, 1967, Cancer.

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds.

N. Brock, J. Pohl, J. Stekar, 1981, European journal of cancer.

Prevention of urotoxic side effects by regional detoxification with increased selectivity of oxazaphosphorine cytostatics.

N. Brock, J. Pohl, 1986, IARC scientific publications.

The problem of specificity and selectivity of alkylating cytostatics; studies on N-2-chloroethylamido-oxazaphosphorines

N. Brock, H. Hohorst, 2004, Zeitschrift für Krebsforschung und Klinische Onkologie.

[On the relation between the chemical composition and the cancerotoxic effect in a series of phosphamide esters of bis-(beta-chloroethyl)-a mine].

N. Brock, H. Arnold, F. Bourseaux, 1961, Arzneimittel-Forschung.

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna).

N. Brock, J. Pohl, W. Scheef, 1982, European journal of cancer & clinical oncology.

[Alkylating substances in serum and urine after injection of cyclophosphamide].

N. Brock, H. Hohorst, A. Ziemann, 1965, Arzneimittel-Forschung.

Identification and quantification of metabolite conjugates of activated cyclophosphamide and ifosfamide with mesna in urine by ion-pair extraction and fast atom bombardment mass spectrometry.

M. Przybylski, N. Brock, P. Hilgard, 1985, Biomedical mass spectrometry.

The development of mesna for regional detoxification.

N. Brock, J. Pohl, 1983, Cancer treatment reviews.

Oxazaphosphorine Cytostatics: Structure—Activity Relationships, Selectivity and Metabolism, Regional Detoxification

N. Brock, 1983 .

Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds

N. Brock, J. Pohl, J. Stekar, 2004, Journal of Cancer Research and Clinical Oncology.

Perspectives Studies on the Urotoxicity of Oxazaphosphorine Cytostatics and its Prevention.* 2. Comparative Study on the Uroprotective Efficacy of Thiols and Other Sulfur Compounds in Cancer Research

N. Brock, J. Stekar, Degussa Pharma-Gruppe, 1981 .

Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.

N. Brock, J. Pohl, J. Stekar, 1981, European journal of cancer & clinical oncology.

High-dose ifosfamide and mesna as continuous infusion over five days--a phase I/II trial.

N. Brock, J. Pohl, H. O. Klein, 1983, Cancer treatment reviews.

The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.

N. Brock, 1980, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[Pharmacological characterization of cyclic nitrogen mustard phosphamide esters as cancer therapeutic agents].

N. Brock, 1958, Arzneimittel-Forschung.

Pharmacokinetics and metabolism of sodium 2-mercaptoethanesulfonate in the rat.

S. Orrenius, N. Brock, J. Pohl, 1983, Cancer research.

The Basis of Modern Ifosfamide Therapy1

N. Brock, J. Pohl, 1987 .

Activation of cyclophosphamide in man and animals

N. Brock, R. Gross, H. O. Klein, 1971, Cancer.

Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.

N. Brock, J. Schnitker, E. Fichtner, 1976, Arzneimittel-Forschung.

Electron microscopic investigations of the cyclophosphamide-induced lesions of the urinary bladder of the rat and their prevention by mesna.

H. Themann, N. Brock, J. Pohl, 1987, Urologia internationalis.

The significance of different substrates for tissue metabolism.

N. Brock, H. Druckrey, W. Loch, 1943 .

[Effect of a cyclic nitrogen mustard-phosphamidester on experimentally induced tumors in rats; chemotherapeutic effect and pharmacological properties of B 518 ASTA].

N. Brock, H. Wilmanns, 1958, Deutsche medizinische Wochenschrift.

[ON THE ACTIVATION OF CYCLOPHOSPHAMIDE IN VIVO AND IN VITRO].

N. Brock, H. Hohorst, 1963, Arzneimittel-Forschung.

[On the problem of the effectiveness of d-glyceraldehyde].

N. Brock, T. Niekamp, 1965, Zeitschrift fur Krebsforschung.

Pharmacological studies with alkylsulfonyloxyalkyl substituted and chloroethyl substituted oxazaphosphorine-2-oxides. 1. Communication: relationship between chemical structure and pharmacological action.

J. Kuhlmann, N. Brock, 1974, Arzneimittel-Forschung.

4-Ketocyclophosphamide, a metabolite of cyclophosphamide. Formation, chemical and biological properties.

N. Brock, H. Hohorst, A. Ziemann, 1971, Arzneimittel-Forschung.

Models and methods for the assessment of cumulation of drug effects.

N. Brock, B. Schneider, 1980, Arzneimittel-Forschung.

[Pharmacology of Avacan].

N. Brock, 1951, Deutsche medizinische Wochenschrift.

Pharmacological and chemotherapeutic properties of cyclic and non-cyclic phosphoramide esters.

N. Brock, 1960, Acta - Unio Internationalis Contra Cancrum.

Pharmacokinetics and Metabolism of Sodium 2-Mercaptoethanesulfonate in the Rat 1

S. Orrenius, N. Brock, K. Ormstad, 2006 .